Things I’ve Learned Here Last Week
1. The share price of a start-up biotech like Anavex exactly correlates to, exactly reflects the real science of a company’s proprietary technologies. Price low, as with AVXL, the underlying science must necessarily be flawed. The market is exquisitely “efficient,” knowing hidden things about complicated biochemistry and neurology that blokes posting statements on some online message board couldn’t, themselves, possibly know or understand. The current share price is always the truth, no matter.
2. Likewise, the share price accurately foretells the future of every sort of corporate outcome: clinical trials, FDA drug approvals, company survival. AVXL share prices have been declining for some time, therefore a) there is reduced or absent chance any of the three clinical trials will even start, b) or, if they do, they will all fail with no consequent FDA approval for any molecule in the Anavex pipeline. Share prices, remarkably, determine the results of future clinical trials.
3. Same thing about corporate management. Low and/or declining share prices always, necessarily indicate poor management. Simple, even universal concept — good management necessarily causes share prices to rise; conversely, bad management causes share prices to decline.
4. The solution to the bad management/low share prices problem is simple. Fire the guys. Any one else would do a better job. Share prices, then, would go up.
5. Anavex principals, from the CEO on down to the scientific personnel, are dumb; couldn’t see, anticipate, or plan for changes in clinical trial results or new FDA drug trial protocols. They were and are locked into last-century thinking into drug trials and drug development. No hope.
And, a bunch more. But no need to lay out any more revealed Anavex negatives. Scrutinizing readers of this investment forum, like all who post here, weigh things at the highest intellectual levels, have reached their own understandings of Anavex Life Sciences Corp, pro or con, bull or bear.
I have a tendency to forget things I learn. By the time the market opens Tuesday morning, inept as I am, I will have forgotten everyone of the five big things I learned here last week. I will forget to liquidate my small AVXL position, unable to turn those few funds around into an equity that has none of the five listed problems. Feel sorry for me, please. In a year or two, I’ll have forgotten the entire matter. I’ll be Ok.
AI
